Introduction
Peripheral T-cell lymphomas (PTCL) are rare cancers, which stand for about 10% of all nonHodgkin's lymphomas (NHL) (Harris et al., 1994 ; The. Non-Hodgkin's.Lymphoma.Classification. Project, 1997) . They represent a heterogeneous group of neoplasms, which display a great variability in their clinical, morphological, immunophenotypic, cytogenetic and molecular features (Harris et al., 1994) . The World Health Organization (WHO) classification recognizes only two well-characterized nodal PTCL entities, namely angioimmunoblastic lymphomas (AIL) and anaplastic large-cell lymphomas (ALCL) (Harris et al., 1994) . In fact, although a number of morphological subtypes of PTCL have been described in the past, such as Lennert's lymphoma, T-zone lymphoma, pleomorphic T-cell lymphoma, or T-immunoblastic lymphoma (Suchi et al., 1987) , evidence that these correspond to distinct clinicopathological entities is still lacking (Harris et al., 1994; Gisselbrecht et al., 1998) . For this reason, the rest of nodal PTCLs are now referred as 'unspecified' (PTCL-U) (Harris et al., 1994) . Since the prognosis of PTCL-U is usually poor, with more than half of the patients dying of their disease (Gisselbrecht et al., 1998) , it would be useful to improve their classification to allow more adapted treatments.
Large-scale expression studies have already shown their ability to improve the classification of lymphoid tumors. Analysis of several B-NHLs series has led to the definition of molecular subgroups with specific outcomes (Alizadeh et al., 2000; Rosenwald et al., 2002; Shipp et al., 2002; Thieblemont et al., 2004) . In contrast, only a limited number of T-cell neoplasms have been investigated using microarrays, including mycosis fungoides (Tracey et al., 2003) , leukemic phase of cutaneous T-NHL (Kari et al., 2003) , cell lines derived from T-cell malignancies (Li et al., 2001; Fillmore et al., 2002) , or PTCL (Martinez-Delgado et al., 2004) . A recent profiling analysis was focused on the comparison between PTCL and T-lymphoblastic lymphoma (T-LBL) types (Martinez-Delgado et al., 2004) , but a molecular classification of PTCL entities has not yet been reported.
We used gene expression profiling to identify distinct, yet unrecognized subtypes of PTCL-U, and to determine whether this single broad category could be divided into distinct molecular diseases. Our results support the existence of three molecular subgroups of PTCL-U.
Results
From the entire set of genes present on the microarray, we identified 4.716 cDNAs significantly expressed in a majority of samples. Hierarchical clustering of this subset of genes was performed in order to classify the 59 T-NHLs samples according to their gene expression patterns.
Identification of tumor subtypes
As shown in Figure 1 , hierarchical clustering revealed complex variations in gene expression profiles among T-cell lymphomas. Seven groups of samples could be discriminated as shown on the top of Figure 1a and zoomed in Figure 1b . Genes discriminating these groups of samples were identified using a Student t-statistics. They are shown on the right part of Figure 1a as dots displaying the same color as the sample group that they discriminate. Discriminating genes were grouped in 10 clusters (colored rectangles on the right part of Figure 1a and are zoomed in Figure 1b) . This hierarchical clustering overlapped the WHO classification, since most samples classified in one of the WHO well-characterized entities (WCE), that is, AIL, ALCL, or T-LBL, were separated into independent molecular clusters. Most AIL samples were gathered in the red branch, and T-LBL samples in the orange branch. ALCL samples were closely related, although there was a segregation between the three ALK-negative cases and the two ALK-positive cases (located in light and dark green branches, respectively). In contrast, PTCL-U samples did not form a single subset, as they clustered in three different branches (dark blue, pink and brown branches), except rare samples that were found in the AIL branch. The three main branches containing PTCL-U samples (U1: dark blue; U2: pink; U3: brown) were associated with specific gene expression profiles, as shown in Figure 1b .
The ALCL cluster (light green) included genes involved in early response (FOS, JUN, EGR, EGFR), stromal remodeling (COL6A1, COL7A1, CALD1, GJB1, KRT6A, KRT10, MMP3, MMP1, TIMP1) and cell proliferation (VEGF, VEGFB, DTR, EGFR, TGFB). Some of these genes are known to be expressed in ALCL, such as CTLA1-GZMB, FOS, JUN, MCL-1 and IL13RA2 (Kagami et al., 1999; Petit et al., 2001; Rassidakis et al., 2002; Villalva et al., 2002) . The T-LBL cluster (orange) contained genes involved in cell proliferation (PCNA, CDC2, E2F1, CDKN2A, Ki67, MADH2, MAX, MYC, CDK2, CDK4, CDK10, CDK8), cell-cycle (TP53BP2, TP53, CCNA1, CCND3) and cytoskeleton biology (tubulins A1, B2, B4, G1). The AIL cluster (red) was mainly structured around immunoglobulin genes (IGHM, IGHG, IGHA, IGLC). The PTCL-U1 cluster contained genes expressed in connective and muscle tissues (TPM1, TPM2, MYH1, COL18A1, COL4A2, TNNC2, TNNT1, TNNI1). The PTCL-U2 cluster included genes involved in translation (RPL13a, RPL26L1, RPL5, RPS16, RPS27A, RPS3A, RPS7), intracellular signaling (AK1, CSNK2A1, CKB, PPP1CC, NFKB1) and apoptosis (VAV2, WIT-1, TCTP, AKT1). The PTCL-U3 cluster was characterized by genes expressed in the monocyte-macrophage lineage (CD14, CD44, CD59, CD63, CD81, CSF1, MIP1), coding for various chemokines (MCP1-CCL2, CCL3, CCL4, CCL5, IP10-CXCL10, MIG-CXCL9, IL10), cathepsins (CTSB, CTSC, CTSD, CTSS), or class II MHC proteins (HLA-DPB1, HLA-DMA), as well as genes involved in the interferon response pathway (STAT1, JAK1, JAK2, IFNAR1, GBP1, IFI30, CBL-B).
Histiocyte-rich T-NHL samples (stars on Figure 1b ) including two Lennert's NHL samples (triangles on Figure 1b ) mainly belonged to the PTCL-U3 subgroup. Normal T-cell samples clustered together in the hierarchical clustering when they were simultaneously analysed with NHL samples, but did not show significant similarity with any of the T-cell lymphoma subgroups (data not shown). Thus, they were not represented in the final clustering to allow a better clarity.
WCE classifier
The hierarchical clustering strongly suggested that WCE (AIL, ALCL and T-LBL) could be distinguished at the transcriptional level. To confirm this, we built a molecular predictor of WCE using the multiclass predictor method described in Thieblemont et al. (2004) . Genes discriminating each WCE from the others were searched using a t-statistics at 0.1% risk. Figure 2a shows the expression profile of the 90 genes discriminating individual WCE. Mean WCE profiles were built, and Pearson's correlations of individual samples with these mean profiles were calculated (Figure 2b ). Prediction was correct for the majority of WCE samples, whereas most PTCL-U samples were not significantly correlated with WCE (Figure 2b and c) . Altogether, these data suggest that most PTCL-U samples do not share any significant molecular similarity with either AIL, ALCL, or T-LBL.
PTCL-U classifier
We then used the same method to confirm the existence of the three PTCL-U branches observed in the initial clustering. Figure 3 shows the expression profiles of the 255 genes defining PTCL-U subgroups. Most PTCL-U samples could be predicted in one of the three subgroups, except five samples. Three out of these five samples had been already predicted as AIL or ALCL with the WCE classifier. In addition, three samples initially diagnosed as 'borderline (BL) AIL' that T-cell lymphoma gene expression profiling B Ballester et al segregated into the PTCL-U branches of the hierarchical clustering could be predicted as PTCL-Us by the PTCL-U classifier. These results suggest that most PTCL-U samples can be classified into three classes, called PTCL-U1, -U2 and -U3, corresponding to independent molecular entities.
Functional annotation of T-NHL subtypes using Gene Ontology (GO)
To assess the biological functions associated with T-NHL subtypes, we searched for specific under-and overassociations of GO terms with the genes discriminating these subtypes, using GoMiner. In all, 65 biological functions were significantly associated with T-NHL subtypes as shown in Figure 4 . Sets of GO terms associated with T-NHL distinction delineated very coherent functions. For example, in the case of T-LBL, the over-represented GO terms (cell cycle, DNA metabolism, regulation of transcription, cell proliferation, cytokine activity, etc.) underlined the proliferative state of T-LBL cells. Interestingly, some T-NHL subtypes were associated with similar biological functions, although they did not share any common discriminating genes in their signature. This is the case of GO terms associated with immunological functions, which were over-represented in ALCL, AIL and PTCL-U3, and under-represented in T-LBL and PTCL-U2 subtypes. More specific associations could be observed, such as over-representation of GO terms associated with proliferation in T-LBL, signalization in ALCL, MCH class II in AIL, translation in PTCL-U2, and under-representation of GO terms associated with proliferation in AIL.
A striking result was obtained with the PTCL-U1 subtype, which was significantly associated with muscle GO terms, probably due to the significant overexpression of seven genes, including myosin (MYH1), tropomyosins (TPM1 and TPM2) and troponins (TNNC, TNNT, TNNI) ( Figure 1c ). These latter genes are expressed in muscle cells, including smooth muscles associated with blood vessels (Pinet et al., 2004) . It is unlikely that this profile could be explained by an active angiogenesis process in PTCL-U1, since this Correlations between each sample and WCE mean profiles were calculated. Only the best correlation is shown. The correlations below the significance threshold (horizontal strong line) correspond to samples not predicted as any WCE class. Prediction was correct for the majority of WCE samples (a and b, color dots). In contrast, almost none of the PTCL-U samples displayed significant correlation with WCE (b and c, black dots), thereby indicating that most PTCL-U samples do not share significant molecular similarity with WCE.
T-cell lymphoma gene expression profiling B Ballester et al subgroup did not show significant overexpression of any gene involved in angiogenesis, including VEGF, VEGFR and angiopoietin. Another explanation could be the presence of some muscle fibers trapped during lymph node resection.
Prognosis of PTCL-U Differences in survival between the three PTCL-U subgroups were analysed using log-rank test. PTCL-U2 and -U3 share the same overall survival. In contrast, PTCL-U1 patients tended to have a worse outcome Figure 1 : blue for U1, pink for U2 and brown for U3. The above panel (a) shows the expression profiles of the three PTCL-U molecular subsets according to genes discriminating PTCL-U samples, derived from the hierarchical clustering shown in Figure 1 . Panel b shows the predictive index. Correlations between each sample and the three PTCL-U mean profiles were calculated. Only the best correlation is shown. The correlations below the significance threshold (horizontal strong line) correspond to rare samples not predicted as any PTCL-U class (black dots). In contrast, most samples diagnosed as PTCL-U on histophenotypical grounds are correctly classified since they display a high correlation with the PTCL-U mean molecular profile (color dots).
T-cell lymphoma gene expression profiling B Ballester et al when compared to other PTCL-U subtypes, but this difference was not significant. These preliminary data must be taken with caution due to the low number of cases in each PTCL-U subgroup, and obviously require further confirmation.
Validation of DNA microarrays results by RQ-PCR analysis
The levels of mRNA evaluated by RQ-PCR were correlated with the microarrays data for each tested gene. The results are summarized in the Supplementary Figure 1 . As expected from the microarray data, the highest levels of RQ-PCR CCND2 expression were observed in a sample belonging to the PTCL-U1 subgroup. Similarly, when analysed by RQ-PCR, expression of STAT1 was higher in PTCL-U3 samples than in other samples. The highest TIMP1 expression was found in an ALCL sample, and the highest XBP1 expression was in an AIL sample. Gene Ontology (GO) profile analysis. For each set of genes significantly discriminating any lymphoma subtype, under-and over-representation of GO terms were searched using GoMiner. The terms significantly (at 0.1% risk) associated with any T-NHL subtype are shown as colored squares (green for under-represented terms, and red for over-represented terms).
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Proteomic validation using tissue microarray (TMA) Among the different antibodies tested anti-STAT1, anti-BCL-2 and anti-CCND2 antibodies gave significant positive signals. We observed a BCL-2 IHC staining in a variable proportion of atypical, neoplastic lymphocytes in 18/28 analysed PTCL samples. These results were correlated with microarray data, since four out of four samples belonging to the PTCL-U2
group showed a high number of positive cells, whereas BCL-2 staining was either heterogeneous or negative in the other cases (Figure 5a-c) . IHC expression of STAT1 could be evidenced on 16/28 PTCL TMA samples, with a great variation in the percentage of positive cells from case to case. The signal was mainly located in reactive histiocytes, occasional reactive lymphocytes and plasmocytes, whereas neoplastic shows high amounts of histiocytes; the TMA core from the same case (e, left) shows an intense STAT1 immunostaining when compared with a case from the PTCL-U2 subgroup (e, right). High-power view of STAT1 staining shows that the signal is located in the cytoplasm and nucleus of reactive histiocytes (f, stars), whereas atypical neoplastic cells are negative (f, arrow). Low-power view (g) of CCND2 immunostaining in a PTCL-U1 case shows positivity in a fraction of tumor cells (arrows), which correspond to atypical neoplastic cells at high-power view (h, arrow).
T-cell lymphoma gene expression profiling B Ballester et al cells were negative. The intensity of staining and the number of positive cells were higher in the four cases belonging to the PTCL-U3 subgroup than in the other positive cases (Figure 5d and e). In these four cases, a frequent nuclear staining was observed (Figure 5f ), whereas the staining was mainly cytoplasmic in the other cases. CCND2 immunostaining was present in 5/28 cases, including three out of three cases belonging to the PTCL-U1 group. In these five positive cases, the signal was located in the nucleus of atypical, neoplastic cells (Figure 5g and h) . In summary, IHC data were correlated with microarray analysis, since all samples with a high level of mRNA expression, characterizing the signature of a specific PTCL-U subset, also showed significant expression of the corresponding protein. However, the correlation was not strict enough for class predicting, since some unrelated samples that expressed low to moderate mRNA levels also variably expressed the protein. Similar limited correlations between microarray and TMA have been previously observed in other types of tumors, such as breast cancer (Ginestier et al., 2002) .
Discussion
Whereas gene profiling has been extensively used to unravel the molecular basis of B-NHLs subtypes (Alizadeh et al., 2000; Shipp et al., 2002; Thieblemont et al., 2004) , a molecular portrait of PTCL has not yet been established. The present report describes a molecular taxonomy of nodal T-NHLs that supports the WHO classification, since it could separate AIL, ALCL and T-LBLs according to specific gene expression signatures.
The main contribution of the present work is to improve the understanding of the WHO provisional PTCL-U type, by defining three distinct, yet unrecognized, distinct molecular PTCL-U subgroups. A previous attempt to divide PTCL-U has been carried out using IHC (Tsuchiya et al., 2004) . It suggested the existence of a 'Th1' group with features of Th1 differentiation reminding those observed in AILs, and a 'Th2 group' displaying a Th2 phenotype resembling ALCLs. However, this interesting approach was based on the expression of a limited number of markers. In the present report, the hierarchical clustering shows that PTCL-U samples segregated in three distinct branches associated with different gene expression signatures, which we called PTCL-U1, PTCL-U2 and PTCL-U3.
The PTCL-U1 gene expression signature was characterized by overexpression of genes known to be associated with poor outcome and/or aggressive behavior in various tumor cells, such as overexpression of CCND2 (Lossos et al., 2004) . Overexpression of SIX3, coding for a homeotic coactivator of nuclear receptor, is also known to deregulate expression of target genes towards uncontrolled tumor growth (Hisaoka et al., 2004) . Histopathological review of PTCL-U1 lesions showed a tendency to harbor relatively scarce reactive cells, which suggests a low degree of immune activation in this group. This is supported by the overexpression of RGS10, coding for a member of the RGS family of proteins that negatively regulates chemokines effects (Shi et al., 2004) , and the absence of significant cytokine/chemokine overexpression.
The PTCL-U2 subtype gene expression signature was characterized by genes involved in translation, signal transduction and apoptosis. This signature included NFKB1 and BCL-2, whose expression correlates with poor outcome in DLCL (Alizadeh et al., 2000) . NFKB1, as well as many genes in this cluster, play an essential role in oncogenesis, as suggested by the constitutive NFKB activity previously described in many tumors. Overexpression of NFKB1 and BCL-2 may also reflect the involvement of an activation pathway, since NFKB is a major component of the T-cell activation signature and is known to induce expression of antiapoptotic genes like BCL-2 (Shaffer et al., 2001) .
The PTCL-U3 gene signature was mainly characterized by genes related to the macrophage/histiocyte lineage, such as CD14, MIP1, cathepsins, CSF1 and HLA class II. This profile was correlated with histological features, since most PTCL-U3 samples exhibited a relatively abundant reactive macrophage component and could be qualified as 'histiocyte-rich' PTCL-U. The most relevant PTCL-U3 genes encoded two closely related IFNg-inducible chemokines (IP10-CXCL10 and MIG-CXCL9) that are largely produced by stimulated macrophages (Hiroi and Ohmori, 2003a, b) . The signature also included STAT1, JAK2 and some IFNinducible genes such as GBP1 (interferon-induced guanylate-binding protein 1), IFI30 (gamma-interferon-inducible protein IP-30). This expression profile suggests the activation of the canonical IFNg/JAK2/ STAT1 signaling pathway. The positive STAT1 immunostaining that we observed in both the nucleus and cytoplasm of macrophages from PTCL-U3 samples also supports this hypothesis, since binding of IFNg receptors results in phosphorylation of JAK2, which in turn leads to the phosphorylation of STAT1 and its subsequent translocation to the nucleus (Ramana et al., 2002) .
Both the reliability of our methodology and the robustness of our PTCL-U algorithm are supported by our results regarding WCE. In fact, despite a small number of samples, we could clearly separate T-LBLs from PTCLs, on the basis of a specific gene signature. This signature was mainly driven by 'proliferation' gene clusters, including cell-cycle regulation/checkpoint and cyclin-dependent kinases genes. This is an expected finding since T-LBL are known to display the highest proliferation rates among T-NHLs (Harris et al., 1994) . This clearcut molecular segregation between LBL and PTCL, also recently reported using the same approach (Martinez-Delgado et al., 2004) , further supports the totally distinct pathogenesis of these two main groups of T-cell neoplasms.
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The AIL signature was mainly represented by two tight gene clusters, characterized by the overexpression of various B-cell markers including immunoglobulin genes. Other main components of this signature were XBP1 and RUNX1. This signature is in accordance with a known distinctive feature of AIL lesions, which is the presence of an expanded B-cell population (Dogan et al., 2003) . Overexpression of XBP1 suggests that this transcription factor could play a role in the development of B-cell hyperplasia in AIL lesions, since it is known to be a crucial factor influencing B-cell and plasma cell differentiation (Chauhan et al., 2003; Munshi et al., 2004; Shaffer et al., 2004) . RUNX1 may also be related to AIL pathogenesis, since it is known to be often overexpressed in acute leukemia (Cameron and Neil, 2004) .
The ALCL signature included genes involved in early response, extracellular matrix and cell proliferation. This signature is in accordance with previous data, since it comprises genes already described as overexpressed in ALCL such as MCL-1 (Rassidakis et al., 2002 (Rassidakis et al., , 2003 Villalva et al., 2002) , CTLA1-granzyme B (Kagami et al., 1999) , TP53 (Petit et al., 2001) and JUNB (Villalva et al., 2002) . Some features of our ALCL signature, like overexpression of IL13R, FOS and JUNB, suggest a Th2 differentiation (Mao et al., 2003) , which is also in accordance with previous IHC findings (Tsuchiya et al., 2004) . As far as we are aware, the present report is one of the first gene profiling study in which a systematic functional analysis was carried out using GO. The GO term analysis of biological functions associated with T-NHL subtypes led to coherent correlations with the respective function of each gene discriminating these subtypes. Moreover, since this method represents an objective and systematic approach to evaluate the functional aspects of gene signatures, it offers the advantage to disclose unexpected results, such as the association of the PTCL-U1 subtype with muscle GO terms, which remains uneasy to explain and requires further clarification. From a functional standpoint, it is also noteworthy that the lack of similarity between the expression profiles of normal T-cell and tumors suggests that the cell-of-origin model that was used for the molecular taxonomy of B-NHLs is more difficult to apply in T-NHLs, probably due to the abundance and heterogeneity of the reactive cell component in T-cell NHLs.
In conclusion, it can be stressed out that our molecular PTCL classification is complementary to classical histophenotypical criteria. In fact, some PTCL samples, which were initially qualified as 'BL' because they displayed ambiguous histophenotypical features, could be unequivocally included in either PTCL-U, AIL or ALCL molecular groups using the multiclass predictors. In addition, the molecular taxonomy of PTCL-U highlights the pathogenesis of these tumors, especially the involvement of the JAK/STAT pathway in the PTCL-U3 subgroup. Further larger studies are needed to investigate the prognostic value and usefulness of this molecular subclassification in the management of PTCL-U patients.
Materials and methods

Selection of samples
In all, 59 lymph node biopsy samples from four different institutions were retrospectively analysed. These samples were obtained at the time of initial diagnosis prior to any therapy. They were classified as PTCL-U (n ¼ 32), AIL (n ¼ 19) and ALCL (n ¼ 5). As comparative controls, we also included three T-LBL, and 13 normal lymphoid cells samples from seven patients, including normal tonsil, unstimulated total T cells from peripheral blood (PB), CD3/CD28-costimulated total PB T cells, CD3/CD28-costimulated CD4 PB T cells and CD3/CD28-costimulated CD8 PB T cells. All biopsy samples were reviewed by a panel of hematopathologists (JB, LX, PG) and were investigated by immunohistochemistry (IHC) using at least CD3 and CD20. According to morphological patterns, some cases were also stained for CD30, ALK1, CD10, CD23 and EBV-LMP1. The respective amount of neoplastic/reactive cells was evaluated on histophenotypical grounds. Seven PTCL-U samples that contained a significant number (more than 30%) of plasma cells and/or B cells were qualified as 'BL'. In all, 10 samples in which reactive histiocytes were numerous and formed significant aggregates were qualified as 'histiocyte rich', including two samples in which atypical T cells were masked by huge amounts of histiocytes, corresponding to the definition of the so-called Lennert's lymphoma (Suchi et al., 1987) . The diagnosis of AIL was considered on the basis of usually admitted criteria (Dogan et al., 2003) . AIL samples that lacked one of these criteria were qualified as 'BL'. ALCL samples were all CD30 positive, and were either ALK positive (two cases) or ALK negative (three cases). Clinical data, including follow-up, could be obtained in most cases. All patients had signed informed consent for biopsy analysis.
Messenger RNA samples Total RNA was extracted from samples by lysis in guanidium isothiocyanate (Trizol reagent, Gibco BRL, Grand Island, NY, USA) using standard protocols. According to the size of the tumor, up to ten 50 mm sections were used for RNA extraction and three to five sections were collected for future DNA extraction. One 6 mm section was used for hematoxylin and eosin (HES) staining and histological control. RNA integrity was controlled by denaturing formaldehyde agarose gel electrophoresis. RNA quality and quantity were assessed by electrophoresis and optical density respectively (Agilent, Bioanalyser).
Microarray procedures
Briefly, each of the RNA samples was hybridized on a separate microarray providing from the same printing batch and containing 8016 spotted cDNA clones representing 7874 IMAGE clones related to carcinogenesis and 142 control clones. Several quality control steps were taken. Before each RNA hybridization, the quality of spotting, including the determination of target DNA amount accessible for each spot, was controlled by hybridization of each microarray with a 33 P-labeled oligonucleotide sequence common to all PCR products (Bertucci et al., 1999) . After stripping, microarrays were hybridized with 33 P-labeled probes made from total RNA. Other quality controls included the use of negative (empty cloning vector, polyA clones, mouse cDNA clones, blank PCR) and positive controls (cG03 clones corresponding to spikes). Details about microarrays construction, clones list, probe preparations, hybridizations and washes are described at http://tagc.univ-mrs.fr/pub/. After washing, hybridization images were obtained by scanning with an imaging device (Fuji BAS 5000, Raytest, Paris, France). Scanned images were automatically quantified (Lopez et al., 2004) . The reproducibility of our nylon microarray procedure has been previously checked and proved to be satisfactory . Moreover, repeated hybridization of a same lymphoma sample always showed a good reproducibility with a correlation always above 0.98.
Data analysis
Normalization and data analysis Before analysis, all data were subjected to print-tip Lowess normalization (Yang et al., 2002) implemented in the statistical software package R (Ihaka and Gentleman, 1996) . Data were further corrected for the amount of spotted cDNA (Bertucci et al., 1999) . From the initial set of 7.824 genes related to carcinogenesis, 4.716 were significantly expressed in a majority of samples and were kept for further analysis. Hierarchical clustering was obtained with Genesis software (Sturn et al., 2002) using correlation distance and average linkage method.
Multiclass predictor A multiclass predictor was constructed as described previously (Thieblemont et al., 2004) . Genes discriminating particular lymphoma subtypes (AIL, ALCL, LBL, PTCL-Us) were searched using a t-statistic at 0.1% risk. A mean profile was determined for each lymphoma subtypes and Pearson's correlations between individual samples and mean profiles were calculated.
Correlations greater than 0.55 for known T-NHL and 0.4 for PTCL-U were considered as significant at 0.1% risk. This threshold was calculated by generating bootstrapped profiles, in which expression of each gene was randomly chosen from the observed values of that gene. Samples exhibiting no significant correlation with any subset profile were considered as unpredictable. Kaplan-Meier plots and log-rank test were calculated using SPSS (http://www.spss.com/).
Functional annotation Functional annotation of genes discriminating each lymphomas subtype was performed using GO (Ashburner et al., 2000) and GoMiner (Zeeberg et al., 2003) . Significance of over-or under-representation was calculated using Fisher's exact test at 0.1% risk. Hierarchical classification (Euclidian distance and average linkage) of GO terms and T-NHL lymphomas was obtained by encoding significant over-representation by 1 (red) and significant underrepresentation by À1 (green).
Real-time PCR analysis In order to validate cDNA array data, we selected four genes (CCND2, TIMP1, STAT1, XBP1) that were differentially expressed among the different T-NHL subgroups. Their expression level was analysed by RQ-PCR in eight relevant T-NHL and in normal PB lymphocyte (PBL) mRNA samples. GAPDH was used as the endogenous RNA and cDNA quantity control (Lossos et al., 2004) . Total RNA (2.5 mg) was subjected to reverse transcription using random primers and Superscript II (Invitrogen). cDNA ( 1 10 th) was used as the template for amplification of STAT1, TIMP1, XBP1 and GAPDH transcript, using LightCycler FastStart DNA MasterPLUS SYBR Green I (Roche Diagnostics Gmbh, Mannheim, Germany) on a LightCycler 2.0 Instrument (Roche Diagnostics). Primers for STAT1 (forward primer, 5 0 -ATCA CATTCACATGGGTGG-3 0 ; reverse primer, 5 0 -CTTCAGGG GATTCTCAGGAATA-3 0 ); TIMP1 (forward primer, 5 0 -GTGGGGACACCAGAAGTCAA-3 0 ; reverse primer, 5 0 -GTGGGACCTGTGGAAGTA-3 0 ); XBP1 (forward primer, 5 0 -ATGGATTCTGGCGGTATTG-3 0 ; reverse primer, 5 0 -GA GAAAGGGAGGCTGGT-3 0 ) and GAPDH (forward primer, 5 0 -GTCATCCCTGAGCTAGACGG-3 0 ; reverse primer, 5 0 -GGGTCTTACTCCTTGGAGGC-3 0 ) were designed according to the LightCycler Probe Design 1.0 Software (Roche Diagnostics). PCR reaction using these primers gave a single band on agarose gel (not shown). Analyses of the quantitative real-time PCR curves were performed by means of the LightCycler 3.5 Software (Roche Diagnostics). All samples were run in triplicate. Normal PBLs were used as a reference sample. Amplification of the GAPDH gene was used as a normalization control for each sample. CCND2 PCR analysis was carried out using ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA). GAPDH primers used for the ABI PRISM 7700 sequence detection system were as follows: 5 0 -CCC TGG TGA CCA GGC-3 0 (forward) and 5 0 -TGG CAA CAA TAT CCA CTT TAC CAG AGT-3 0 (reverse), designed and manufactured by Applied Biosystems (P/N 4326317E). CCND2-specific primers were 5 0 -TAC TTC AAG TGC GTG CAG AAG GAG-3 0 (forward), and 5 0 -TCC CAC ACT TCC AGT TGC GAT CAT-3 0 (reverse).
TMA preparation and IHC
The TMA was constructed as described previously (Ginestier et al., 2002) . Briefly, 2 mm core of each paraffin-embedded tumor was obtained and inserted in a recipient paraffin block using a manual tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). The TMA samples included 23 PTCL cases, normal lymph nodes (n ¼ 8) and normal nonhematolymphoid tissues (n ¼ 3). The diagnostic value of each core was assessed by hematoxylin and eosin staining on 5-mm-thick sections cut from the TMA. TMA (5 mm) sections were mounted on pretreated ChemMate slides (DakoCytomation, Glosturp, Denmark), deparaffinized and then rehydrated. IHC was carried out at room temperature in a Dako Autostainer (DakoCytomation) as described previously (Ginestier et al., 2002) . Slides were pretreated with 0.1% H 2 O 2 , and then with DAKO blocking serum (DakoCytomation). We selected a panel of antibodies directed against gene products characteristic of each PTCL-U subset: STAT1 (9H 2 , Cell Signaling Technology, Beverly, MA, USA), BCL-2 (DakoCytomation, Glosturp, Denmark) and CCND2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Primary antibodies were applied for 1 h, after washing, a secondary biotinylated anti-mouse antibody (DakoCytomation) was applied for 20 min, and then a streptavidin-conjugated peroxidase (Dako LSAB-2 s kit, DakoCytomation) and 3,3 0 -diaminobenzidine tetrahydrochloride (DakoCytomation) were applied according to the manufacturer's instructions. Slides were counterstained with hematoxylin. Two pathologists (LX and OR) assessed IHC staining. The type of immunopositive cells was recorded for each TMA core.
